JP2016520550A - マトリクスメタロプロテイナーゼおよびその使用 - Google Patents

マトリクスメタロプロテイナーゼおよびその使用 Download PDF

Info

Publication number
JP2016520550A
JP2016520550A JP2016506654A JP2016506654A JP2016520550A JP 2016520550 A JP2016520550 A JP 2016520550A JP 2016506654 A JP2016506654 A JP 2016506654A JP 2016506654 A JP2016506654 A JP 2016506654A JP 2016520550 A JP2016520550 A JP 2016520550A
Authority
JP
Japan
Prior art keywords
mmp
tissue
inactive
mmps
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016506654A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520550A5 (https=
Inventor
ジルバーバーグ，クラウディア
ビー． フィールズ，グレッグ
ビー． フィールズ，グレッグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016520550A publication Critical patent/JP2016520550A/ja
Publication of JP2016520550A5 publication Critical patent/JP2016520550A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24017—Stromelysin 1 (3.4.24.17)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24024—Gelatinase A (3.4.24.24), i.e. matrix metalloproteinase 2 or MMP2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24034—Neutrophil collagenase (3.4.24.34)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24065—Macrophage elastase (3.4.24.65), i.e. metalloelastase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
JP2016506654A 2013-04-05 2014-04-04 マトリクスメタロプロテイナーゼおよびその使用 Pending JP2016520550A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361808861P 2013-04-05 2013-04-05
US61/808,861 2013-04-05
PCT/US2014/033009 WO2014165780A2 (en) 2013-04-05 2014-04-04 Matrix metalloproteinases and uses thereof

Publications (2)

Publication Number Publication Date
JP2016520550A true JP2016520550A (ja) 2016-07-14
JP2016520550A5 JP2016520550A5 (https=) 2017-05-25

Family

ID=51659357

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016506654A Pending JP2016520550A (ja) 2013-04-05 2014-04-04 マトリクスメタロプロテイナーゼおよびその使用

Country Status (15)

Country Link
US (1) US20160053250A1 (https=)
EP (2) EP2981276A4 (https=)
JP (1) JP2016520550A (https=)
KR (1) KR20160006694A (https=)
CN (1) CN105246500A (https=)
AU (1) AU2014248002A1 (https=)
BR (1) BR112015025390A2 (https=)
CA (1) CA2908739A1 (https=)
CR (1) CR20150603A (https=)
HK (1) HK1221405A1 (https=)
MX (1) MX2015014053A (https=)
PH (1) PH12015502306A1 (https=)
RU (1) RU2015147878A (https=)
SG (1) SG11201508199QA (https=)
WO (1) WO2014165780A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105412916B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗乳腺癌的组合物及其用途
CN105477627B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 治疗前列腺癌的组合物及其用途
CN105412917B (zh) * 2014-09-19 2021-04-30 达森生物药业有限公司 治疗实体瘤的抗癌组合物及其用途
CN105477628B (zh) * 2014-09-19 2021-04-30 山东蓝金生物工程有限公司 抗癌组合物及其用途
JPWO2017038473A1 (ja) * 2015-08-28 2018-06-14 天野エンザイム株式会社 エンドトキシン低減サーモリシン
CN105907840A (zh) * 2016-03-29 2016-08-31 苏州大学 单细胞水平检测mmp酶活性的方法
US10137179B2 (en) * 2016-05-18 2018-11-27 Hyalo Technologies, LLC Composition and method of preparation of protease microparticulate slow release preparation
CN108451981B (zh) * 2018-04-21 2019-07-23 江西汉氏联合干细胞科技有限公司 使用皮肤间充质干细胞治疗系统性硬化症
US12569594B2 (en) 2018-12-20 2026-03-10 The Steadman Clinic And Steadman Philippon Research Institute Decellularized tendon matrix methods and uses thereof
CN114377150B (zh) * 2021-12-29 2023-10-13 中山大学南昌研究院 一种mmp酶敏感胎盘微环境和肿瘤微环境靶向载体及其制备方法和应用
CN116549325B (zh) * 2022-01-27 2025-07-29 南京大学 一种组合物、其制备方法、制剂及应用
CN119530138B (zh) * 2024-12-05 2026-01-30 中国肉类食品综合研究中心 一种用于工业化细胞解离的多酶制剂及其使用方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521931A (ja) * 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞を収集及び保存するための改善された組成物、及び該組成物の使用方法
WO2009125859A1 (ja) * 2008-04-07 2009-10-15 財団法人ヒューマンサイエンス振興財団 薬剤、歯科材料、及びスクリーニング方法
US20100247512A1 (en) * 2006-03-31 2010-09-30 The Regents Of The University Of Michigan Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
JP2012080882A (ja) * 2003-10-08 2012-04-26 Vet-Stem Inc 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5770691A (en) * 1995-06-05 1998-06-23 Regents Of The University Of Minnesota Discriminatory substrates for MMP hydrolysis
ES2317657T3 (es) 1996-09-19 2009-04-16 The Regents Of The University Of Michigan Polimeros que contienen polisacaridos tales como alginatos o alginatos modificados.
US6531154B1 (en) 1997-06-10 2003-03-11 Brown University Research Foundation Modulated release from biocompatible polymers
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
WO1999055396A1 (en) 1998-04-27 1999-11-04 Surmodics, Inc. Bioactive agent release coating
US6376742B1 (en) 1999-02-17 2002-04-23 Richard J. Zdrahala In vivo tissue engineering with biodegradable polymers
WO2000051662A1 (en) 1999-03-04 2000-09-08 Tepha, Inc. Bioabsorbable, biocompatible polymers for tissue engineering
KR100392501B1 (ko) 2000-06-28 2003-07-22 동국제약 주식회사 다중 에멀젼법에 의한 서방출성 미립구의 제조방법
EP1611233B1 (en) * 2003-04-08 2016-01-06 Yeda Research And Development Co., Ltd. Stem cells having increased sensitivity to sdf-1 and methods of generating and using same
SE0302559D0 (sv) * 2003-09-25 2003-09-25 Astrazeneca Ab Method
MX2010003019A (es) * 2007-09-19 2010-04-30 Pluristem Ltd Celulas adherentes de los tejidos adiposo y de placenta y uso de las mismas en la terapia.
US8222206B2 (en) * 2008-03-04 2012-07-17 Taiwan Advance Bio-Pharm Inc. Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
US9435811B2 (en) * 2008-09-30 2016-09-06 Oriental Yeast Co., Ltd Inducer of chondrocyte proliferation and differentiation
CA2794165A1 (en) * 2010-03-24 2011-09-29 Lifenet Health Bmp-4 peptides & methods of use
EP2608809B1 (en) * 2010-08-27 2019-05-22 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012080882A (ja) * 2003-10-08 2012-04-26 Vet-Stem Inc 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
JP2009521931A (ja) * 2005-12-29 2009-06-11 アントフロゲネシス コーポレーション 胎盤幹細胞を収集及び保存するための改善された組成物、及び該組成物の使用方法
US20100247512A1 (en) * 2006-03-31 2010-09-30 The Regents Of The University Of Michigan Pericellular Collagenase Directs the 3-Dimensional Development of White Adipose Tissue
WO2009125859A1 (ja) * 2008-04-07 2009-10-15 財団法人ヒューマンサイエンス振興財団 薬剤、歯科材料、及びスクリーニング方法

Also Published As

Publication number Publication date
HK1221405A1 (zh) 2017-06-02
MX2015014053A (es) 2016-04-07
EP2981276A4 (en) 2017-03-22
AU2014248002A1 (en) 2015-11-19
PH12015502306A1 (en) 2016-02-15
US20160053250A1 (en) 2016-02-25
RU2015147878A (ru) 2017-05-10
CR20150603A (es) 2016-04-04
SG11201508199QA (en) 2015-11-27
CN105246500A (zh) 2016-01-13
BR112015025390A2 (pt) 2017-08-29
EP2981276A2 (en) 2016-02-10
EP3290047A1 (en) 2018-03-07
WO2014165780A3 (en) 2014-12-18
CA2908739A1 (en) 2014-10-09
WO2014165780A2 (en) 2014-10-09
KR20160006694A (ko) 2016-01-19

Similar Documents

Publication Publication Date Title
JP2016520550A (ja) マトリクスメタロプロテイナーゼおよびその使用
El Fahime et al. In vivo migration of transplanted myoblasts requires matrix metalloproteinase activity
Peçanha et al. Adipose-derived stem-cell treatment of skeletal muscle injury
Almalki et al. Effects of matrix metalloproteinases on the fate of mesenchymal stem cells
US10035834B2 (en) Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
EP2968315B1 (en) Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP2021105015A (ja) ナノ粒子組成物、その製剤およびその使用
JP6847664B2 (ja) Ｐ９７−ポリヌクレオチド複合体
ES2661587T3 (es) Tratamiento de enfermedad vascular periférica usando células derivadas de tejido del cordón umbilical
Xiong et al. Human adipose tissue‑derived stem cells alleviate radiation‑induced xerostomia
Zriek et al. Mesenchymal stromal cell secretome: immunomodulation, tissue repair and effects on neurodegenerative conditions
EP3568154B1 (en) Compositions and methods for treating farber disease
AU2018257071A1 (en) Peptide for inducing regeneration of tissue, and use thereof
EP2155237B1 (en) Glycosylasparaginase for treatment of cancer
EP3080246A2 (en) Compositions and methods for producing and administering brown adipocytes
US6825167B1 (en) Genetic modification of endostatin
US20040071687A1 (en) Adult stem cell recruitment
AU760252B2 (en) Modulation of cell proliferation, methods and reagents
KR102544139B1 (ko) 피부 경화증의 치료를 위한 매트릭스 금속단백분해효소를 포함하는 자가 유래 세포의 전달
US12527842B2 (en) Composition for preventing or treating bone diseases comprising CCR2
Zhang et al. Sustained‐Release Sitagliptin Microneedles for Scar Prevention via Fibroblast‐to‐Adipocyte Conversion
Yin et al. Sustained released of microRNA-99b-3p abundant exosomes derived from adipose stem cell encapsulated with hydrogel microparticles (HMPs) for long-term osteoarthritis treatment
WO2024100421A1 (en) Sarm1 inhibitors for use in therapy and cosmetics
KR100574597B1 (ko) α1β1 인테그린 수용체 저해제 및 ＴＧＦ-β1 저해제의신장 질환의 치료용 용도
US11554158B2 (en) GPNMB compositions for treatment of skin wounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170403

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180904